Immunic, Inc. (IMUX) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
the bull case· 2
16
disclosed supplier and customer ties named in SEC filings
sec filingsedgar56
managers reporting a position in thirteen f filings
13fJun 30 '26the bear case· 3
13
managers whose positions together make up four fifths of reported value
13fJun 30 '2619 of 21
largest reporting managers that cut their stake in the latest quarter
13fJun 30 '26−85.14%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 9 '26 report. Not a forecast, not advice.
tall tick = annual report · 1 on record
Immunic, Inc. has no measured co-movers clearing our correlation floor, so only its SEC classification is shown.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
High 10.68 at 2:15 pm ET, low 10.23 at 11:45 am ET.
Immunic, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
IMUX (Immunic, Inc.) has 16 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
56 managers report a position worth $133.1M between them, and 13 of them hold 80% of it.